Summary & Overview
HCPCS Level II J9003: Leuprolide injectable (camcevi etm), 1 mg
HCPCS Level II code J9003 designates a 1 mg unit of leuprolide injectable (camcevi etm), a specialty hormonal therapy used in clinical contexts such as oncology and certain hormone-responsive conditions. As an HCPCS Level II drug code, J9003 matters nationally because it standardizes billing for this injectable formulation across outpatient infusion centers, physician offices, and ambulatory care sites. Clear identification supports accurate claims submission, reimbursement consistency, and drug utilization tracking.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for leuprolide injectables, typical sites of service, and what to expect from claims coding tied to unit-based HCPCS billing. The publication summarizes national benchmarking considerations, common billing scenarios, and recent policy or coding clarifications affecting specialty injectable drugs.
This resource is intended to help billing professionals, practice managers, and policy analysts understand the role of HCPCS Level II code J9003 in the revenue cycle, how it fits into outpatient injectable workflows, and where to look for payer-specific coverage and reimbursement details.
Billing Code Overview
HCPCS Level II code J9003 describes Leuprolide injectable (camcevi etm), 1 mg. This HCPCS entry represents a packaged medication unit used for injectable leuprolide formulations.
-
Service type: Prescription injectable medication administration related to leuprolide therapy
-
Typical site of service: Outpatient infusion centers, physician office administration, and ambulatory care settings where injectable oncology or specialty hormonal therapies are provided
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is a 45-year-old female with symptomatic uterine fibroids or endometriosis or a metastatic prostate cancer patient requiring androgen suppression, presenting to an outpatient infusion clinic for administration of J9003 (Leuprolide injectable, camcevi etm, 1 mg). The clinical workflow begins with a provider visit documenting indication, consent, and medical history. A medication order is entered into the electronic health record specifying dose and frequency (often monthly or three-month depot equivalents adjusted from mg units). Nursing performs pre-injection assessment (vitals, allergies, pregnancy test if applicable), prepares the product per manufacturer instructions, and administers via subcutaneous or intramuscular injection according to the prescribed regimen. Post-administration monitoring focuses on immediate injection-site reactions and vital sign stability before discharge with follow-up instructions and scheduling of subsequent injections.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
25 | Significant, separately identifiable evaluation and management service by the same physician on the same day of the procedure | Use when a same-day E/M visit is medically necessary and documented in addition to the injection visit |